Silver Book Fact

A proteasome inhibitor was found to reduce pain and joint destruction in an animal model of osteoarthritis, suggesting that nontoxic proteasome inhibitors could offer a novel pharmacotherapy option.

Ahmed A, Li J, Erlandsson-Harris H, Stark A, et al. Suppression of Pain and Joint Destruction by Inhibition of the Proteasome System in Experimental Osteoarthritis. Pain. 2012; 153(1): 18-26. http://journals.lww.com/pain/Abstract/2012/01000/Suppression_of_pain_and_joint_destruction_by.8.aspx

Reference

Title
Suppression of Pain and Joint Destruction by Inhibition of the Proteasome System in Experimental Osteoarthritis
Publication
Pain
Publication Date
2012
Authors
Ahmed A, Li J, Erlandsson-Harris H, Stark A, et al
Volume & Issue
Volume 153, Issue 1
Pages
18-26
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.  
  • An opiate agonist often used for persistent pain, tramadol was found in one meta-analysis to significantly reduce neuropathic pain when compared to placebo.  
  • Use of stem cells to create neurons could enable the study of the response of human cells to new drugs in vitro, early in the drug development process.  
  • An oral cannabinoid was found effective in relieving diabetic peripheral neuropathic pain symptoms and improving disturbed sleep, quality of life, and overall patient status.  
  • Pain education programs and pain consultations have been found to improve pain (average pain was 31% versus 20%) and daily interference (20% versus 2.5%) in oncology outpatients. Patient adherence…